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Abstract 
The purpose of this report is to describe the experimental procedure used 
to perform a preliminary study to characterise the metabolic competence 
of in vitro cellular systems. 
As a first study, the metabolic competence was assessed by monitoring 
the presence of four specific enzymes by using selected probe substrates. 
Each probe substrate can be metabolised by only one enzyme and 
therefore the formation over time of metabolites is indicative for the 
presence of a certain enzyme. The concentrations of each metabolite 
over-time were measured by using liquid chromatography coupled with 
tandem mass spectrometry (LC-MS/MS). 
The method developed to monitor the presence of the four enzymes was 
then used to compare the metabolic competence between two cellular 
systems: HepaRG (human liver cells known to be metabolically 
competent) and AR-CALUX (human osteoblastic osteosarcoma U2-OS 
cells having low or none metabolic activity). 
The results and experience achieved will serve to ultimately support the 
planned work of Directorate F3 focused on developing an EURL ECVAM 
recommendation, which will be followed by an OECD Guidance Document, 
with the objective to characterise and describe in vitro hepatic metabolic 
clearance methods in order to facilitate their regulatory uptake and use to 
support chemical risk assessment.  
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1 Introduction 
Modern toxicology is relying more and more on the use of alternative 
methods to animal testing in order to predict if a chemical can be 
potentially toxic to humans. 
The traditional approach, which is still highly used to support regulatory 
chemical risk assessment, is the administration of different doses of a 
chemical to animals with the scope to evaluate if the chemical causes 
adverse effects. 
For a variety of reasons, from ethical considerations on animal welfare to 
the need generate more accurate information on chemical's toxicity in 
less time and with less resources, several in vitro cell methods have been 
developed or are under development.  
In vitro methods are based on a biological system which can be either a 
cellular system (e.g a specific cell type representing a targeted human 
organ as the liver, kidney, lung, etc.) or a sub-cellular system (e.g 
enzymes isolated from a specific cell or cellular membranes, etc.). 
The general workflow to predict chemical's toxicity by using in vitro tests 
implies exposing cells (or sub-cellular fractions) to several concentrations 
of a certain chemical to then measure biological endpoints that are 
informative of the chemical toxicity. 
In other words, the objective is to evaluate what the chemical does to the 
biological system and this process is also called dynamics. 
However also the cellular system does something to the chemical and this 
process is called kinetics. In a cellular system the kinetics process 
involves the direct excretion of the chemical from the cell, or its metabolic 
biotransformation to other chemicals species (metabolites) which can 
facilitate the excretion from the cell. The cellular metabolism (or in vitro 
metabolic clearance) is in many cases the main driving process of in vitro 
kinetics to determine the concentration-time profile of a chemical in 
cellular system. 
To summarise, the interaction between an in vitro cellular system and a 
chemical implies both kinetics and dynamics processes which happen in 
parallel and their combination can influence the manifestation of a toxic 
effect caused by exposure to a chemical. 
Therefore, the kinetics, and particularly the in vitro metabolism, plays an 
important role in the manifestation of potential toxicity since it influences 
the amount of a chemical over time that can interact with the biological 
system and eventually causes toxicity. 
Prediction of in vivo toxicity by using in vitro assays is promising but 
there are still limitations particularly to predict complex toxicological 
endpoints.  
There are several explanations why in vitro data fail to predict certain in 
vivo endpoints and one of these is the difference in metabolic clearance, 
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and in general of metabolic machinery, between in vitro- and in vivo- 
assays. 
A different metabolic pathway of the in vitro assay might then hamper the 
relevance of the in vitro data when they are used to predict the in vivo 
counterpart. 
For example, a chemical might be considered toxic based on the in vitro 
data even if in vivo results show no toxicity. One possible explanation is 
that the in vitro system used for toxicity testing is not metabolically 
competent and therefore the chemical accumulates within the cell causing 
toxicity. This does not happen in in vivo where the chemical is 
metabolised to a non-toxic metabolite which is then excreted from the 
cells without causing toxicity. 
Therefore the metabolic characterisation of an in vitro test system, to 
evaluate the level of similarity of the metabolic machinery with the in vivo 
counterpart, can serve to select the most suitable in vitro system and to 
better assess the relevance of in vitro data when used to predict chemical 
toxicity. 
The metabolic machinery is comprised of several enzymes also called 
biotransformation enzymes and its characterisation should monitor the 
presence of each enzyme or of those of interest for a specific purpose. 
Biotransformation is usually divided into two main phases, phase I and 
phase II. Phase I is usually oxidative (e.g. hydrolysis, although reductive 
metabolism and non-redox reactions of functionalization can also occur), 
and has a major protective function in making lipophilic molecules more 
polar and therefore facilitating their excretion.  In phase II, which is often 
called as detoxification phase, the chemicals oxidised in phase I are 
subsequently conjugated with highly polar molecules, such as glucuronic 
acid, to further facilitate their excretion. 
The metabolic characterisation, e.g. the identification of the presence of 
Phase I and Phase II biotransformation enzymes in a biological cell, tissue 
or subcellular fraction, is generally performed by incubating a probe 
substrate which can be metabolised by only one specific enzyme and 
measuring the metabolite formed. The rate of metabolite formation, 
expressed as pmol/min/mg protein is the expression of the activity of 
each specific enzyme. The characterisation of multiple enzymes requires 
the use of multiple probe substrates. 
For metabolic characterisation, the cells, tissues or subcellular fractions 
are exposed with one or multiple probe substrates at different incubation 
time-points and the known metabolites are usually measured using 
dedicated analytical methods and instrumentation such as liquid 
chromatography-tandem mass spectrometry (LC-MS/MS). 
This report describes a preliminary work performed at EURL ECVAM to 
characterise the metabolic competence of in vitro cellular systems. EURL 
ECVAM is interested to better characterise in vitro cellular systems as a 
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mean to improve their evaluation in the context of how they can be used 
to support chemical risk assessment. Therefore, the assessment of 
metabolic competence is one parameter to be considered when 
characterising the properties of in vitro cellular systems. 
In this study, the presence of the following four biotransformation 
enzymes was characterised by using specific probe substrates selected 
from previous literature studies [1]: 
 Cytochrome P450 2E1 (CYP2E1) 
 Monoamine oxidase (MAO) 
 Uridine 5'-diphospho-N-acetylgalactosamine glycosyltransferase 
(UGT) 
 N-Acetyltransferase (NAT) 
These enzymes were selected since they have a broad coverage of both 
phase I and phase II metabolism. 
The method was implemented, and used to characterise the metabolic 
competence of the following two in vitro cellular systems: AR-CALUX cells 
and CryoHepaRG. 
HepaRG cells, which are human liver cells of cancer origin, are known to 
be metabolically competent and they have a similar metabolic machinery 
to the one of primary human hepatocytes. Whereas, AR-CALUX are 
human osteoblastic osteosarcoma U2-OS cells having low or no metabolic 
activity.  
Therefore this study was performed, as proof of concept, to compare the 
metabolic machinery of two cell lines known to represent to different 
situations. 
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2 Materials and Methods 
2.1 General experimental layout 
In this study, the metabolic competence of two cell lines, CryoHepaRG 
and AR-CALUX, was evaluated and compared by monitoring the presence 
of the following four enzymes: CYP2E1, MAO, UGT and NAT. 
Each cell line was exposed for 1 h to each individual probe substrate, at 
two different concentrations in triplicates, in order to start the incubation. 
Each probe substrate is specifically metabolised by only one of the four 
above enzymes to be monitored. Therefore, the presence of the selected 
enzymes is evaluated by measuring the specific metabolites, eventually 
formed, from each of the probe substrates. 
At the end of the incubation period (1 h), the selected metabolites 
eventually formed are measured by LC-MS/MS analysis. 
Figure 1 represents the experimental layout. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HepaRG 
AR-CALUX 
Each of the following individual probe substrates: 
 Chlorzoxazone, 50µM 
 Chlorzoxazone, 500µM 
 Kynuramine, 50µM 
 Kynuramine, 500µM 
 7-Hydroxycoumarin, 80µM 
 7-Hydroxycoumarin, 250µM 
 Isoniazid, 250µM 
 Isoniazid, 500µM 
1 hour incubation 
LC-MS/MS analysis of the following eventually formed 
metabolites: 
 6-Hydroxychlorzoxazone 
 4-Hydroxyquinoline 
 7-Hydroxycoumarin glucuronide 
 Acetyl isoniazide 
Figure 1 
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2.2 Materials 
2.2.1 Chemicals: 
− Chlorzoxazone (CAS No. 95-25-0, Sigma-Aldrich) 
− 6-Hydroxychlorzoxazone (CAS No. 1750- 45- 4, Carbosynth) 
− Kynuramine (CAS No. 363-36-0, Chemos) 
− 4-Hydroxyquinoline (CAS No. 611-36-9, Sigma-Aldrich) 
− 7-Hydroxycoumarin (CAS No. 93-35-6, Sigma-Aldrich) 
− 7-hydroxycoumarin glucuronide sodium salt (CAS No. 66695-14-5, 
Carbosynth) 
− Isoniazid (CAS No. 54-8-3, Sigma-Aldrich) 
− Acetyl isoniazide (CAS No. 1078-38-2, Carbosynth) 
− 5,5-Diethyl-1,3-diphenyl-2-iminobarbituric acid, DDIBA (CAS No. 
200116-26-3, Sigma-Aldrich) used as internal standard for LC-MS 
analysis. 
 
 
2.2.2 Cells, cell media and additives: 
 
CryoHepaRG cells (Biopredic) 
 
− Williams’ Medium E 
− 200 mM L-glutamine 
− HepaRG® Thaw, Seed and General Purpose Supplement (contains 
serum, Invitrogen, HPRG670) 
− HepaRG® Induction Supplement (with no serum, Invitrogen, 
HPRG650) 
− 1 M Hepes buffer 
 
 
AR-CALUX cells (BioDetection Systems, BDS) 
 
− DMEM supplemented with F12 with phenol red 
− DMEM supplemented with F12 without phenol red 
− 7.5% Foetal Calf Serum, FCS 
− 5% Dextran-Coated Charcoal treated FCS 
− 1% non-essential amino acids 
− 10 Units/ml Penicillin 
− 10 µg/ml Streptomycin 
− 0.02% Geneticin 
 
 
 
 7 
 
2.2.3 Plastic-ware and disposable: 
For CryoHepaRG cells: 
− 1.5 ml, 15 ml und 50 ml centrifugation tubes, conically shaped, 
polypropylene, sterile; 
− 96-well plates with lid, uncoated, polypropylene; 
− 96-well plates coated with collagen I, qualified for seeding and 
culture of CryoHepaRG® (e.g. Biopredic International, PLA136) 
 
For AR-CALUX cells: 
− Clean or sterile glass tubes or vials; 
− Sterile pipettes, 1, 2, 5, 10 and 25 ml; 
− Sterile tips, 10, 100, 200, 1000 and 5000 µl; 
− 96-well plates with lid, uncoated, polypropylene; 
− Cell culture flasks 75 cm2; 
 
2.2.4 Technical Equipment: 
 
− 37ºC cell culture incubator with a 5±1% CO2 atmosphere and 
saturated humidity 
− Water bath able to maintain a temperature of 37°C 
− Centrifuge 
 
2.2.5 Instrument used for chemical analysis: 
HPLC 1100 G1312A (Agilent) coupled with API 4000 Triple Quadrupole 
(Perkin-Elmer Sciex Instruments) 
 
2.3 Enzymes monitored and corresponding probe substrates 
 
Table 1 
Enzyme Phase of 
metabolism 
Probe Substrate 
added to cells 
Metabolite formed 
CYP2E1 I Chlorzoxazone 6-Hydroxychlorzoxazone 
Mono Amine 
Oxidase 
I Kynuramine 4-Hydroxyquinoline 
Uridine 5'-
diphospho-N-
acetylgalactosamine 
glycosyltransferase 
II 7-Hydroxycoumarin 7-Hydroxycoumarin 
glucuronide 
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N-Acetyltransferase II Isoniazid Acetyl isoniazide 
2.4 Material Preparation 
2.4.1 HepaRG: 
2.4.1.1 Preparation of HepaRG basal medium: 
 
1) Transfer 99 mL Williams's Medium E in a plastic container  
2) Add 1 mL of L-Glutamine 200 mM         
3) Shake thoroughly and label as “HepaRG basal medium” 
4) Assign an expiry date of 1 month 
 
2.4.1.2 Preparation of HepaRG Thaw, Seed and General 
Purpose Medium (contains serum): 
 
1) HepaRG® Thaw, Seed and General Purpose Supplement (contains 
serum) is thawed by placing the vial (12.5 mL) into a 37°C water 
bath. Then the volume is transferred into a new plastic bottle 
2) Add 100 of "HepaRG basal medium" (see section 2.4.1.1) 
3) Shake thoroughly and label as “HepaRG Thaw, Seed and General 
Purpose Medium” 
4) Assign an expiry date of 1 month 
 
 
2.4.1.3 HepaRG Serum-Free Induction Medium: 
 
1) HepaRG Induction Supplement (with no serum) is thawed by 
placing the vial (0.6 mL) into a 37°C water bath. Then the volume 
is transferred into a new plastic bottle 
2) Add 100 of "HepaRG basal medium" (see section 2.4.1.1) 
3) Shake thoroughly and label as “HepaRG® Serum-Free Induction 
Medium” 
4) Assign an expiry date of 1 month 
 
2.4.1.4 Incubation Medium: 
 
 
1) Take a bottle of 500 mL Williams's Medium E and use it for the 
following steps: 
2) Add 5 mL of L-Glutamine 200 mM         
3) Add 12.5 mL of HEPES        
4) Shake thoroughly and label as “Incubation medium” 
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5) Assign an expiry date of 1 month 
 
2.4.1.5 Thawing and culturing of CyroHepaRG cells: 
 
Note 1: 1 vial contains about 8 million of cryopreserved HepaRG. Since, 
for one experiment (where all the 4 probe substrates are added to cells at 
two concentrations each in triplicates), each well contains 72000 cells, 1 
vial is sufficient to perform an experiment following the layout shown in 
following Figure 2. 
Note 2: the thawing must be performed on a Friday and the seeded cells 
are allowed to settle over the weekend in 96-wells plates 
The thawing and culturing of CyroHepaRG cells have been previously 
described [2], below are the critical steps of the protocol 
1. Pre-warm HepaRG Thaw, Seed and General Purpose Medium (see 
section 2.4.1.2)  to 37°C for about 10-20 min 
2. Transfer 9 ml of pre-warmed HepaRG Thaw, Seed and General 
Purpose Medium to a sterile 50 mL polystyrene tube 
3. Carefully remove the vial from the cryostorage 
4. Immerse the vial into a 37°C water bath. Shake it gently for 
about 1.5 minutes until the ice is detached from the plastic. It is 
very important that the vial is not submerged completely to avoid 
water penetration into the cap. Furthermore, small ice crystals 
should remain when the vial is removed from the water bath 
5. Transfer the vial to the laminar flow hood and disinfect it with an 
absorbent paper containing isopropanol or ethanol 
6. From the vial, transfer all CyroHepaRG cells suspension into the 
pre-warmed 50 mL polystyrene tube containing 9 mL of 
HepaRG® Thaw, Seed and General Purpose Medium 
7. From the 50 mL polystyrene tube, use 1 mL of solution to rinse 
the vial once. Then, transfer back 1 mL into the 50 mL 
polystyrene tube 
8. Re-suspend the hepatocytes suspension by gently inverting the 
50 mL polystyrene tube 3 times 
9. Centrifuge the 50 mL polystyrene tube at 350 g at room 
temperature for 2 minutes 
10. Discard the supernatant by aspirating using a vacuum pump 
11. Add 5 mL of pre-warmed HepaRG Thaw, Seed and General 
Purpose Medium to the 50 mL polystyrene tube. Then, using a 
pipette, pipette gently for loosening the pellet 
12. Determine the total cell count and the percentage of viable cells 
using the Trypan Blue exclusion method 
13. After determination of the cell concentration (expressed as 
cells/mL), add additional pre-warmed Cell Medium to obtained 
the desired concentration of cells (for the incubation assay 
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72000 cells in 100 µL are needed. Therefore the desired 
final concentration is 720000 cells in 1 mL of Cell Medium) 
Acceptance criteria to use hepatocytes for incubation assay 
 A minimum cell viability , by using the Trypan Blue method, of 80% 
after thawing must be obtained. 
 
14. After reconstitution at the desired concentration (720k/mL), the 
cells are transferred to a 96-well plate coated with collagen I, 
suitable for seeding and culture of CryoHepaRG® (e.g. Biopredic 
International, PLA136)" for seeding. 100 μl (containing 72000 
cells) are transferred to each well (see following Figure 2 for the 
plate layout) 
15. 6 h from after the plating, cells are already attached and the 
medium is replaced with fresh pre-warmed one. Then, the cells 
are left in the incubator at 37°C over the weekend 
16. On Monday, the medium is replaced with HepaRG® Serum-Free 
Induction Medium (see section 2.4.1.3), renewed after 24 h. The 
cells are left in this medium at 37°C for 48h and then they are 
ready to be treated 
 
2.4.2 AR-CALUX: 
2.4.2.1 Preparation of Growth medium: 
 
1) Place a vial of 41 ml of 7.5% Foetal Calf Serum into a 37°C water 
bath for thawing  
2) Open a 500 mL bottle of DMEM/F12 with phenol red in a laminar 
flow cabinet 
3) Add 5.5 ml of non-essential amino acids (MEM 100x) to get 1 % 
4) Add the tube containing the 41 ml of FCS thawed (point 1) 
5) Add 1 ml penicillin-streptomycin solution 
6) Add 2.2 ml Geneticin 
7) Shake thoroughly and label as “Growth Medium” 
8) Assign an expiry date of 1 month 
 
 
2.4.2.2 Preparation of Assay medium: 
 
1) Place a vial of 26.6 ml of 5% Dextran-Coated Charcoal treated FCS 
into a 37°C water bath for thawing 
2) Open a 500 mL bottle of DMEM/F12 without phenol red in a laminar 
flow cabinet 
3) Add 5.5 ml of non-essential amino acids (MEM 100x) to get 1 % 
4) Add the tube containing the 26.6 ml of DCC-FCS (point 1) 
5) Add 1 ml penicillin-streptomycin solution 
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6) Shake thoroughly and label as “Assay Medium” 
7) Assign an expiry date of 1 month 
 
 
 
2.4.2.3 Thawing and culturing of AR-CALUX cells: 
Note 1: The AR-CALUX cells were thawed two weeks before the treatment 
because, according to the acceptance criteria, the cells need to have at 
least 2 passages (two per week) in order to then be used for the 
experiment. For this experiment the cells were grown for 4 passages. 
Note 2: On Tuesday morning of the week of the experiment (in order to 
use AR-CALUX cells with HepaRG ones in the same experiment), the cells 
were re-suspended in assay medium and seeded at 10000 cells/well 
(100l from a 100000 cells/ml cell suspension).  
 
1. From the refrigerator (at 4°C), take the Growth medium (see 
section 2.4.2.1) and pipet 15 ml of it a sterile 50 mL polystyrene 
tube. Then put the 50 mL polystyrene tube back in the 
refrigerator 
2. Pre-warm the remaining growth medium in a water bath at 37°C. 
3. Carefully remove the vial from the cryostorage 
4. Immerse the vial into a 37°C water bath. Shake it gently for 
about 1.5 minutes until the ice is detached from the plastic. It is 
very important that the vial is not submerged completely to avoid 
water penetration into the cap. Furthermore, small ice crystals 
should remain when the vial is removed from the water bath 
5. Transfer the vial to the laminar flow hood and disinfect it with an 
absorbent paper containing isopropanol or ethanol 
6. Retrieve the 50 mL polystyrene tube containing 15 mL of Growth 
Medium which was kept in the refrigerator at 4°C (point 1) and , 
transfer into it all AR-CALUX cells suspension from the vial  
7. From the 50 mL polystyrene tube, use 1 mL of solution to rinse 
the vial once. Then, transfer back 1 mL into the 50 mL 
polystyrene tube 
8. Re-suspend the hepatocytes suspension by gently inverting the 
50 mL polystyrene tube 3 times 
9. Centrifuge the 50 mL polystyrene tube at 250 g at room 
temperature for 5 minutes 
10. Discard the supernatant by aspirating using a vacuum pump 
11. Add 10 mL of pre-warmed Growth Medium to the 50 mL 
polystyrene tube. Then, using a pipette, pipette gently for 
loosening the pellet 
12. Transfer the 10 mL with the cells re-suspended into a culture 
flask 75 cm2 (passage number 0) 
13. Place the culture flask in the incubator at 37°C. 
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14. When the cells reach 85-95% confluence (it takes about 2 days), 
they are trypsinased and then transferred into a new flask 
(passage 1). The seeding density for sub-culturing cells in a 75 cm2 flask 
should be of 110000 cells/mL (1100000 cells per flask of 10 mL) to reach 
the 85-95% confluence in 3 days for the next subculturing day, or it should 
be of 70000 cells/mL (700000 cells per flask of 10 mL) to reach the 85-95% 
confluence in 4 days for the next subculturing day. This is to be taking into 
account to avoid subculturing the cells on weekends 
15. Repeat steps 13 and 14 to reach passage 4 
16. When cells have reached passage 3 or 4 (therefore they can be 
used for the experiment), remove the growth medium 
17. Add in the flask 10 ml of Assay medium (see section 2.4.2.2) and 
transfer to a sterile 50 ml tube. 
18. Determine the total cell count and the percentage of viable cells 
using the Trypan Blue exclusion method 
18. After determination of the cell concentration (expressed as 
cells/mL), add additional Assay Medium to obtained the desired 
final concentration of 100000 cells in 1 mL 
19. After reconstitution at the desired concentration, the cells are 
transferred to "96-well plates with lid, uncoated, polypropylene" 
for seeding. 100 μl (containing 10000 cells) are transferred to 
each well (see following Figure 2 for the plate layout) 
20. The cells are left in the incubator at 37°C for 24 h prior the 
experiment 
 
2.4.3 Preparation of working concentrations of probe substrates: 
Each probe substrate (see Table 1), was prepared at 10 mM in methanol 
(stock concentration). Then each stock was used to prepare the working 
concentrations summarised in Table 2. The working concentrations used 
to expose HepaRG were made in incubation medium (refer to section 
2.4.1.4) while working concentrations used to expose AR-CALUX were 
made in assay medium (refer to section 2.4.2.2) 
 
Table 2 
CYP2E1 
(Phase I) 
MAO (Phase I) UGT (Phase II) 
NAT (Phase 
II) 
Chlorzoxazone Kynuramine 7-Hydroxycoumarin Isoniazid 
conc 1 =   
50µM 
conc 1 =   50 
µM 
conc 1 =   80µM 
conc 1=  
250µM 
conc 2 =   
500µM 
conc 2 =   
500µM 
conc 2 =   250µM 
conc 2 = 
500µM 
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2.5 Method 
 
2.5.1 Study design 
After the culturing of HepaRG and AR-CALUX cells (as described in section 
2.4.1.5 and 2.4.2.3), the assay consists of exposing each cell line to each 
of the four probe substrates at two concentrations in triplicates for 60 
min.  
At the end of the 60 min exposure, the incubation reaction was stopped 
by the addition of a stop solution (acetonitrile containing 5-Diethyl-1,3-
diphenyl-2-iminobarbituric acid, DDIBA used as Internal Standard) and 
the samples were analysed for the specific metabolites shown in Table 1 
by means of LC/MS/MS. 
The 96-well plate layout shown in Figure 2 is then used to expose 
HepaRG or AR-CALUX (one plate/cell type). 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A             
B  Cells  + 
Chlorzoxaz
one 50µM 
Cells + 
Kynuramin
e 50µM 
Cells + 7-
hydroxycoum
arin 80µM 
Cells + 
Isoniazid 
250µM  
 Negative Control 
Cells with no 
chemical)    
 
C  Cells  + 
Chlorzoxaz
one 50µM 
Cells + 
Kynuramin
e 50µM 
Cells + 7-
hydroxycoum
arin 80µM 
Cells + 
Isoniazid 
250µM  
 Negative Control 
Cells with no 
chemical)    
 
D  Cells  + 
Chlorzoxaz
one 50µM 
Cells + 
Kynuramin
e 50µM 
Cells + 7-
hydroxycoum
arin 80µM 
Cells + 
Isoniazid 
250µM  
 Negative Control 
Cells with no 
chemical)    
 
E  Cells  + 
Chlorzoxaz
one 500µM 
Cells + 
Kynuramin
e 500µM 
Cells + 7-
hydroxycoum
arin 250µM 
Cells + 
Isoniazid 
500µM  
 
    
 
F  Cells  + 
Chlorzoxaz
one 500µM 
Cells + 
Kynuramin
e 500µM 
Cells + 7-
hydroxycoum
arin 250µM 
Cells + 
Isoniazid 
500µM  
 
    
 
G  Cells  + 
Chlorzoxaz
one 500µM 
Cells + 
Kynuramin
e 500µM 
Cells + 7-
hydroxycoum
arin 250µM 
Cells + 
Isoniazid 
500µM  
 
    
 
H             
 
 
 
 
Figure 2 
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2.5.2 Incubation assay 
 
1. Pre-warm the working concentrations of probe substrates 
(previously prepared (see section 2.4.3) at 37°C. 
2. Remove from the incubator at 37 °C the two 96-well plates (one for 
HepaRG and one for AR-CALUX, see section 2.4.1.5 and section 
2.4.2.3) 
3. From each plate, remove the cell medium and wash each well twice 
with 100 µL of Incubation Medium (section 2.4.1.4) for HepaRG and 
Assay medium (section 2.4.2.2) for AR-CALUX as shown in Figure 2 
4. After the washing, to each well, as shown in Figure 2 (except to the 
wells labelled as negative control), add 50 µL of the corresponding 
probe substrate (the probe substrates added to HepaRGs were 
prepared in Incubation medium while those for AR-CALUX in Assay 
medium, see section 2.4.3) 
5. Incubate the 96-well plates at 37°C for 60 min 
6. At the end of exposure time, transfer from each well 40 µL of cell 
medium (with no cells since they are still attached) to the 
corresponding well of a new 96-well plate and immediately, to each 
well, add 40 µL of stop solution (containing acetonitrile containing 
,5-Diethyl-1,3-diphenyl-2-iminobarbituric acid, DDIBA Internal 
Standard) 
7. Centrifuge the plates for 10 min at 2,200 g  
8. From each well (containing 80 µL volume) transfer 30 μl volume 
into a new 96-well plate (correspondingly labelled as “LC/MS 
analysis plate”) and diluted with 70 μl H2O. This plate is covered 
with solvent-resistant aluminium foil and stored at -20°C until LC-
MS analysis. 
2.5.2.1 Protein determination 
The two 96-well plates (one for HepaRG and one for AR-CALUX) with the 
cells seeded were then used for the protein determination. 
For the protein determination the Micro BCA TM Protein Assay Reagent Kit 
was used. It is a detergent-compatible bicinchonic acid (BCA) formulation 
for the colorimetric detection and quantitation of total protein. The 
method utilises BCA as the detection reagent for Cu+1 which is formed 
when Cu+2 is reduced by protein in an alkaline environment. A purple 
colored reaction product is formed by the chelation of two molecules of 
BCA with one cuprous ion (Cu+1=). This water soluble complex exhibits a 
strong absorbance at 562nm that is linear with increasing protein 
concentration. 
The BCA assay primarily relies on two reactions. 
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First, the peptide bonds in protein reduce Cu2+ ions from the copper (II) 
sulfate to Cu+ (a temperature dependent reaction). The amount of Cu2+ 
reduced is proportional to the amount of protein present in the solution. 
Next, two molecules of bicinchoninic acid chelate with each Cu+ ion, 
forming a purple-colored complex that strongly absorbs light at a 
wavelength of 562 nm. 
The bicinchoninic acid Cu+ complex is influenced in protein samples by the 
presence of cysteine/cystine, tyrosine, and tryptophan side chains. The 
amount of protein present in a solution can be quantified by measuring 
the absorption spectra and comparing with protein solutions of known 
concentration. 
 
 
2.5.3 LC-MS/MS analysis: 
 
The bioanalytical part was carried out using the Liquid Chromatography 
coupled with Tandem Mass Spectrometry (LC-MS/MS). 
LC-MS/MS methods were developed to quantify the following metabolites: 
6-hydroxy chlorzoxazone, 4-hydroxyquinoline, 7-hydroxycoumarin 
glucuronide and acetylisoniazide formed during incubations with HepaRG 
cells and AR-CALUX® cells.  
The LC-MS/MS parameters optimised for each metabolite are summarised 
in the following tables (Table 3-6). 
 
 
Table 3: 6-Hydroxy chlorzoxazone 
HPLC conditions 
Column Xterra MS C8 5 µm 4.6 x 50 mm (Waters) 
Mobile phase A Water MilliQ+ 0.1 % formic acid 
Mobile phase B Acetonitrile + 0.1 % formic acid 
Injection volume 10 L 
Gradient Step     Total time (min)   Flow (L/min)    %A    % B 
 0      0.00                 400                 95              5 
1      0.50                    400                 95              5 
2      3.50                 400                 5               95 
3      6.50                    400                 5               95 
4      6.60                 400                 95             5 
5      9.60                 400                 95              5 
Retention time 6-hydroxy chlorzoxazone: 4.2 min 
DDIBA: .0 min 
MS conditions 
Scan type Multiple Reaction Monitoring (MRM) 
Polarity Negative 
Ion source Turbo spray 
MRM Transitions 
Compound Q1-Q3 DP CE 
6OH-CZ 
184-120 - 60 - 28 
184-64 - 60 - 42 
184-148 - 60 - 22 
IS DDIBA 334.3-117 - 70 - 30 
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Table 4: 4-hydroxyquinoline 
HPLC conditions 
Column Xterra MS C8 5 µm 4.6 x 50 mm (Waters) 
Mobile phase A Water MilliQ+ 0.1 % formic acid 
Mobile phase B Acetonitrile + 0.1 % formic acid 
Injection volume 10 L 
Gradient Step     Total time (min)   Flow (L/min)    %A    % B 
 0      0.00                 400                 95              5 
1      0.30                    400                 95              5 
2      4.50                 400                 70            30 
3      4.60                    400                   5            95 
4      7.60                 400                   5            95 
5      7.70                 400                 95              5 
6    13.00                 400                 95              5 
Retention time 4-hydroxyquinoline: 4.8 min 
DDIBA: 7.0 min 
MS conditions 
Scan type Multiple Reaction Monitoring (MRM) 
Polarity Positive 
Ion source Turbo spray 
MRM Transitions 
Compound Q1-Q3 DP CE 
4-OH 
quinoline 
146-77 110 45 
146-104 110 32 
  146-128 * 110 30 
146-51 110 70 
DDIBA 336-308 70 30 
 
 
Table 5: 7-Hydroxycoumarin Glucuronide 
HPLC conditions 
Column Xterra MS C8 5 µm 4.6 x 50 mm (Waters) 
Mobile phase A Water MilliQ+ 0.1 % formic acid 
Mobile phase B Acetonitrile + 0.1 % formic acid 
Injection volume 10 L 
Gradient Step     Total time (min)   Flow (L/min)    %A    % B 
 0      0.00                 400                 95              5 
1      3.00                 400                   5            95 
2      5.00                    400                   5            95 
3      5.10                 400                 95              5 
4      8.00                 400                 95              5 
Retention time  HCG: 3.3 minutes 
DDIBA: 4.5 min 
MS conditions 
Scan type Multiple Reaction Monitoring (MRM) 
Polarity Negative 
Ion source Turbo spray 
MRM Transitions 
Compound Q1-Q3 DP CE 
HCG 
337-175 * - 80 - 15 
337-161 - 80 - 30 
337-113 - 80 - 20 
IS DDIBA 334.3-317 - 70 - 30 
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Table 6: Acetylisoniazide 
HPLC conditions  
Column Atlantis Hilic Silica 3 µm 2.1 x 50 mm (Waters) 
Mobile phase A 10 mM Ammonium formate + 0.125 % formic acid 
Mobile phase B Acetonitrile 
Injection volume 5 L 
Gradient Step     Total time (min)   Flow (L/min)    %A    % B 
 0      0.00                 300                   3            97 
1      0.30                   300                   3            97 
2      5.50                 300                 40            60 
3      7.50                    300                 40            60 
4      7.60                 300                   3            97 
5    12.00                 300                   3            97 
Retention time  Acetylisoniazide: 4.3 min 
Gabapentin: 6.1 min 
DDIBA: 0.6 min 
MS conditions 
Scan type Multiple Reaction Monitoring (MRM) 
Polarity positive 
Ion source Turbo spray 
MRM Transitions 
Compound Q1-Q3 DP CE 
Acetyl 
isoniazide 
180-121 * 60 30 
180-138 60 20 
180-120 60 22 
180-79 60 55 
180-66 60 50 
IS GABA 172-154 30 20 
 
 
3 Results 
 
3.1 Incubation assay 
 
The following sections summarise the results of the presence of the four 
selected enzymes in HepaRG cells and AR-CALUX cells. 
 
3.1.1 Presence of CYP2E1 enzyme: 
 
In both cell lines, the concentration of 6-Hydroxychlorzoxazone was not 
detected by LC-MS/MS analysis and therefore the result is that no 
detectable amount of CYP2E1 is present in neither HepaRG nor AR-
CULUX. 
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3.1.2 Presence of MAO enzyme: 
 
Figure 3A shows the graph comparing the concentrations of 4-
Hydroxyquinoline formed (which is indicative of the presence of MAO 
enzyme) after exposure of HepaRG to the probe substrate Kynuramine, 
while Figure 3B shows the results in AR-CALUX cells. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3A Figure 3B 
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3.1.3 Presence of UGT enzyme: 
 
Figure 4 shows the graph comparing the concentrations of 7-
Hydroxycoumarin glucuronide formed (which is indicative of the presence 
of UGT enzyme) after exposure of HepaRG to the probe substrate 7-
Hydroxycoumarin. 
7-Hydroxycoumarin glucuronide was not detected by LC-MS/MS analysis 
in AR-CALUX and therefore the result is that no detectable amount of UGT 
is present AR-CULUX. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 
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3.1.4 Presence of NAT enzyme: 
 
Figure 5A shows the graph comparing the concentrations of acetyl 
isoniazide formed (which is indicative of the presence of NAT enzyme) 
after exposure of HepaRG to the probe substrate Isoniazid, while Figure 
5B shows the results in AR-CALUX cells. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 5A Figure 5A 
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4 Conclusion 
Sensitive and robust analytical methods with good linearity were 
developed for metabolite quantification. 
The results obtained shown that cultured HepaRG cells express enzymatic 
activity for the following biotransformation enzymes: MAO (Phase I), UGT 
and NAT (both Phase II). No CYP2E1 (Phase I) could be detected. Also 
Kanebratt and Andersson [3] observed that the metabolism of 7-
ethoxycoumarin was low, confirming low levels of CYP2E1 although not 
absent. 
Also cultured AR-Calux cells express Phase I and Phase II activities. 
However, the measure activities are about 10 times lower for NAT and 
about 400 times lower for MAO compared to cultured HepaRG cells. No 
enzymatic activity is observed in AR-Calux cells for CYP2E1 (Phase I) and 
UGT (Phase II). 
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